From Heterotaxia to Cancer Treatment

  • Author: ChemistryViews
  • Published: 05 March 2011
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA
  • Source / Publisher: Chemisty & Biology/Elsevier
thumbnail image: From Heterotaxia to Cancer Treatment

In an example of scientific serendipity, researchers at North Carolina State University, USA, have found that a compound useful for studying the origins of intestinal birth defects may also inhibit the growth and spread of cancerous tumors.

Developed by Alex Deiters and team, the compound induces heterotaxia, a disordering or mirror-image inversion of internal organs in frog embryos. The compound is a novel pyridine analog, named heterotaxin after the condition it causes. In studies to determine the cause of these mutations, Nanette Nascone-Yoder and co-workers found that the compound also prevents normal blood-vessel formation and prevents cells from migrating by increasing cellular adhesion.

The pathway most likely to be affected by heterotaxin was the TGF-beta pathway. TGF-beta is known to play a role in the progression of cancerous tumors from normal to metastatic. This makes it a promising lead compound for preventing cancer metastasis.

Article Views: 2086

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

If you would like to reuse any content, in print or online, from, please contact us first for permission. more

Follow on Facebook Follow on Twitter Follow on YouTube Follow on LinkedIn Follow on Instagram RSS Sign up for newsletters

Magazine of Chemistry Europe (16 European Chemical Societies) published by Wiley-VCH